Loading...

TNDM TANDEM DIABETES CARE INC Product Launches 8-K Filing

TNDM

TNDM

TANDEM DIABETES CARE INC

(TNDM)

2025 8-K

Show Summary

Summary

New Product Launches

Financial Statements

Settlement Agreement

Market Expansion

New Product Launches

Financial Statements

Financial Results

Financial Results

Earnings Reports

Appointment of Jean-Claude ...

Agreements with Dexcom

Annual Meeting of Stockholders

Agreement Extension and Pro...

Earnings Reports

FDA Clearance for Tandem Mo...

Private Offering of Convert...

Earnings Reports

Departure of Directors or C...

Departure of Directors

Other Special Situation

Earnings Reports

Resignation of Executive

Financial Results for Q2 2023

Annual Meeting of Stockholders

Earnings Reports

Financial Results and Board...

Completion of Acquisition

Financial Results Announcement

External Links:

On August 6, 2025, Tandem Diabetes Care, Inc. received FDA clearance for its new SteadiSet infusion set, allowing up to seven days of insulin delivery for type 1 diabetes. The company plans to launch this product alongside its t:slim X2 and future Tandem Mobi insulin delivery systems, focusing on manufacturing growth in the coming quarters.

AI Assistant

TANDEM DIABETES CARE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.